Alkermes plc
ALKS
Rang in Aktien
#2720
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Aktienkurs
$41.70
Marktkapitalisierung
$7.00B
Veränderung (1 Tag)
1.16%
Veränderung (1 Jahr)
37.81%
Land
IE
Handel Alkermes plc (ALKS)
Kategorie
Healthcare
P/B-Verhältnis für Alkermes plc (ALKS)
P/B-Verhältnis zum October 2026 TTM: 3.60
Laut den neuesten Finanzberichten und dem Aktienkurs von Alkermes plc beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 3.60. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 3.83.
P/B-Verlauf für Alkermes plc von 2000 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 3.60 | 10.78% |
| 2024 | 3.25 | -15.31% |
| 2023 | 3.83 | -6.47% |
| 2022 | 4.10 | 21.83% |
| 2021 | 3.36 | 13.32% |
| 2020 | 2.97 | 0.60% |
| 2019 | 2.95 | -24.47% |
| 2018 | 3.91 | -44.02% |
| 2017 | 6.98 | 0.28% |
| 2016 | 6.96 | -22.75% |
| 2015 | 9.01 | 47.97% |
| 2014 | 6.09 | 90.80% |
| 2013 | 3.19 | 11.55% |
| 2012 | 2.86 | -24.48% |
| 2011 | 3.79 | 26.08% |
| 2010 | 3.01 | 13.61% |
| 2009 | 2.65 | -28.56% |
| 2008 | 3.70 | -51.57% |
| 2007 | 7.65 | -88.40% |
| 2006 | 65.88 | -71.33% |
| 2005 | 229.77 | 1,111.04% |
| 2004 | 18.97 | -112.86% |
| 2003 | -147.55 | -968.66% |
| 2002 | 16.99 | 80.48% |
| 2001 | 9.41 | -38.69% |
| 2000 | 15.35 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | 73.62% |
US
|
|
| 13.2547 | 268.16% |
US
|
|
| 4.208 | 16.88% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 71.72% |
NL
|
